AbbVie's Humira gets biosim reprieve—and Amgen wins copycat advantage—in patent deal with Samsung Bioepis
admin 5th April 2018 Uncategorised 0In a big win for AbbVie and its best-selling drug—which also happens to be the biggest drug in the world—the company scored another Humira biosimilars settlement that makes it “increasingly unlikely” copycats will launch in the U.S. before 2023. But in Europe, the threat will arrive much sooner.
More: AbbVie's Humira gets biosim reprieve—and Amgen wins copycat advantage—in patent deal with Samsung Bioepis
Source: fierce